Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes

• Published in: JCI insight Vol. 7; no. 17
• Main Authors: Perdigoto, Ana Luisa, Deng, Songyan, Du, Katherine C, Kuchroo, Manik, Burkhardt, Daniel B, Tong, Alexander, Israel, Gary, Robert, Marie E, Weisberg, Stuart P, Kirkiles-Smith, Nancy, Stamatouli, Angeliki M, Kluger, Harriet M, Quandt, Zoe, Young, Arabella, Yang, Mei-Ling, Mamula, Mark J, Pober, Jordan S, Anderson, Mark S, Krishnaswamy, Smita, Herold, Kevan C
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical investigation 08.09.2022
• Subjects: Animals; Autoimmunity; Diabetes Mellitus; Humans; Inflammation Mediators; Mice; Mice, Inbred NOD; Programmed Cell Death 1 Receptor; Tumor Necrosis Factor Inhibitors; Autoimmunity; Adaptive immunity; Diabetes; Cancer immunotherapy

Checkpoint inhibitors (CPIs) targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have revolutionized cancer treatment but can trigger autoimmune complications, including CPI-induced diabetes mellitus (CPI-DM), which occurs preferentiall...